Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2001-3-19
pubmed:abstractText
Ten patients with advanced B-cell lymphoma were treated with a single locoregional injection of CD3xCD19 bispecific and costimulating CD28 monospecific antibodies to activate tumor-infiltrating T-lymphocytes. Antibodies were administered at 4 different dose levels (30 microg, 270 microg, 810 microg, 1,600 microg of each antibody) either by intratumoral or intralymphatic injection. Most patients developed responses within different compartments of the immune systems (T cells, NK cells) subsequent to the antibody application. Comparative studies in 2 patients of which treated as well as untreated lymph nodes were available revealed the up-regulation of T-cell activation markers induced by the antibody injection. Additionally, in 1 patient the induction of apoptosis of lymphoma B cells in the antibody-treated lymph node was observed. Specificity analyses of peripheral blood T cells by means of IFN-gamma ELISpot measurement indicated the recruitment of idiotype-specific T cells, as in 1 out of 3 investigated patients an increased T-cell response toward autologous idiotype peptides could be demonstrated. We conclude that a single injection of CD3xCD19 bispecific antibodies is capable to induce an activation of autologous T lymphocytes if simultaneous costimulatory signaling by CD28 antibodies is provided. Furthermore, our data suggest that at least in some patients lymphoma-specific T cells can be recruited by this immunotherapeutic approach toward B-cell lymphoma.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0020-7136
pubmed:author
pubmed:copyrightInfo
Copyright 2001 Wiley-Liss, Inc.
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
91
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
516-22
pubmed:dateRevised
2007-7-24
pubmed:meshHeading
pubmed-meshheading:11251975-Aged, pubmed-meshheading:11251975-Aged, 80 and over, pubmed-meshheading:11251975-Animals, pubmed-meshheading:11251975-Antibodies, Bispecific, pubmed-meshheading:11251975-Antigens, CD19, pubmed-meshheading:11251975-Antigens, CD28, pubmed-meshheading:11251975-Antigens, CD3, pubmed-meshheading:11251975-Apoptosis, pubmed-meshheading:11251975-CD4-Positive T-Lymphocytes, pubmed-meshheading:11251975-CD8-Positive T-Lymphocytes, pubmed-meshheading:11251975-Cytokines, pubmed-meshheading:11251975-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:11251975-Female, pubmed-meshheading:11251975-Flow Cytometry, pubmed-meshheading:11251975-HLA-DR Antigens, pubmed-meshheading:11251975-Humans, pubmed-meshheading:11251975-Immunoglobulins, pubmed-meshheading:11251975-Immunotherapy, pubmed-meshheading:11251975-In Situ Nick-End Labeling, pubmed-meshheading:11251975-Killer Cells, Natural, pubmed-meshheading:11251975-Leukemia, B-Cell, pubmed-meshheading:11251975-Lymph Nodes, pubmed-meshheading:11251975-Lymphocyte Activation, pubmed-meshheading:11251975-Lymphoma, B-Cell, pubmed-meshheading:11251975-Lymphoma, Follicular, pubmed-meshheading:11251975-Lymphoma, Mantle-Cell, pubmed-meshheading:11251975-Male, pubmed-meshheading:11251975-Mice, pubmed-meshheading:11251975-Middle Aged, pubmed-meshheading:11251975-Models, Biological, pubmed-meshheading:11251975-Phenotype, pubmed-meshheading:11251975-T-Lymphocytes, pubmed-meshheading:11251975-Time Factors, pubmed-meshheading:11251975-Tomography, X-Ray Computed, pubmed-meshheading:11251975-Up-Regulation
pubmed:year
2001
pubmed:articleTitle
Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses.
pubmed:affiliation
University of Cologne, Department of Internal Medicine I, Joseph-Stelzmann-Str.9, D-50925 Cologne, Germany.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase I